Hong Kong – Third batch of subsidies disbursed under Temporary Unemployment Relief Scheme

Third batch of subsidies disbursed under Temporary Unemployment Relief Scheme

*****************************************************************************


     Vetting work of the third batch of applications under the Temporary Unemployment Relief Scheme (the Scheme) has been completed.  Subsidies will be disbursed to more than 57 000 successful applicants, which include about 31 000 applicants with accounts under the Mandatory Provident Fund (MPF) schemes and over 26 000 applicants without MPF accounts.

 

     A Government spokesman said that taking into account the aforementioned 57 000 successful applicants, the Government has already approved more than 150 000 applications.  In addition, SMS messages or emails have been sent to nearly 30 000 ineligible applicants since last week to inform them of the outcome of their application.  The Government is processing the remaining applications in full swing with the aim to disburse subsidies to all eligible applicants within May.                 

 

     When processing applications, the Government-appointed agent may require applicants to provide additional information to verify their eligibility if necessary.  As there are more applications than expected, the Government has increased manpower to expedite the processing of the applications.  Generally, subsidies can be disbursed to eligible applicants with MPF accounts in about four weeks’ time after submitting the application.  As more than 40 per cent of the applications do not have MPF ​​accounts, the processing time of such applications would take longer.

 

     The Government will announce the next batch of successful applicants in due course.  Applicants may log into the dedicated website of the Scheme (www.tur.gov.hk/en/) to check the application status.

Hong Kong – Fourth batch of CoronaVac vaccines arrive in Hong Kong

Fourth batch of CoronaVac vaccines arrive in Hong Kong

******************************************************


     A new batch (the fourth) of about 800 000 doses of the CoronaVac vaccine has been delivered to Hong Kong from Beijing today (October 4). Soon after the arrival of the vaccines, staff carried out stringent checking and inspection on the vaccines in accordance with established procedures to ensure that they comply with the product specifications and that the transportation process follows the relevant cold-chain requirements.

     The Government has launched the COVID-19 Vaccination Programme. Members of the public are encouraged to get vaccinated. Details of the programme can be found at the designated website (www.covidvaccine.gov.hk).

Hong Kong – Batch recall of Nucala Solution for Injection in Pre-filled Pen 100mg/ml (with photo)

Batch recall of Nucala Solution for Injection in Pre-filled Pen 100mg/ml (with photo)

*************************************************************************************


     The Department of Health (DH) today (July 8) endorsed a licensed drug wholesaler, GlaxoSmithKline Limited (GSK), to recall a batch (batch number: 3K4D) of Nucala Solution for Injection in Pre-filled Pen 100mg/ml (Hong Kong Registration Number: HK-66838) from the market as a precautionary measure due to a potential quality defect of the product.

     The DH received notification from GSK today that a fibre was found in one of the finished products which is a quality defect. After assessment, the overseas manufacturer believes that the defect may be originated from a bulk product batch which may affect a number of finished product batches. As a result, the manufacturer decided to recall all the finished product batches. According to GSK, the batch 3K4D is the only affected batch which has been imported and supplied in Hong Kong. As a precautionary measure, GSK is voluntarily recalling the batch from the market.

     The above product is a prescription medicine used for the treatment of severe asthma. According to GSK, the affected batch has been supplied to Hospital Authority, private hospitals and private doctors.

     GSK has set up a hotline (3189 8765) to handle related enquiries.

     “So far, the DH has not received any adverse reaction reports in connection with the batch of product. The DH will closely monitor the recall,” a spokesman for the DH said.

     ​”Patients who are using the above product should not stop using the medicine, but should seek advice from their healthcare professionals for appropriate arrangement,” the spokesman added.